TY - JOUR
T1 - Commercial articulated collaborative in situ 3D bioprinter for skin wound healing
AU - Levin, Aleksandr A
AU - Karalkin, Pavel A.
AU - Koudan, Elizaveta V.
AU - Senatov, Fedor S.
AU - Parfenov, Vladislav A.
AU - Lvov, Vladislav
AU - Petrov, Stanislav
AU - Pereira, Frederiko D.A.S.
AU - Kovalev, Alexey V.
AU - Osidak, Egor
AU - Domogatsky, Sergey P.
AU - Manturova, Natalya E.
AU - Kasyanov, Vladimir
AU - Sergeeva, Natalia S.
AU - Zorin, Vadim L.
AU - Khesuani, Yusef D.
AU - Mironov, Vladimir A.
N1 - Funding Information:
This work was funded by the Ministry of Science and Higher Education of the Russian Federation under the strategic academic leadership program “Priority 2030.”
Publisher Copyright:
© 2023 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited
PY - 2023/1/31
Y1 - 2023/1/31
N2 - In situ bioprinting is one of the most clinically relevant techniques in the emerging bioprinting technology because it could be performed directly on the human body in the operating room and it does not require bioreactors for post-printing tissue maturation. However, commercial in situ bioprinters are still not available on the market. In this study, we demonstrated the benefit of the originally developed first commercial articulated collaborative in situ bioprinter for the treatment of full-thickness wounds in rat and porcine models. We used an articulated and collaborative robotic arm from company KUKA and developed original printhead and correspondence software enabling in situ bioprinting on curve and moving surfaces. The results of in vitro and in vivo experiments show that in situ bioprinting of bioink induces a strong hydrogel adhesion and enables printing on curved surfaces of wet tissues with a high level of fidelity. The in situ bioprinter was convenient to use in the operating room. Additional in vitro experiments (in vitro collagen contraction assay and in vitro 3D angiogenesis assay) and histological analyses demonstrated that in situ bioprinting improves the quality of wound healing in rat and porcine skin wounds.
AB - In situ bioprinting is one of the most clinically relevant techniques in the emerging bioprinting technology because it could be performed directly on the human body in the operating room and it does not require bioreactors for post-printing tissue maturation. However, commercial in situ bioprinters are still not available on the market. In this study, we demonstrated the benefit of the originally developed first commercial articulated collaborative in situ bioprinter for the treatment of full-thickness wounds in rat and porcine models. We used an articulated and collaborative robotic arm from company KUKA and developed original printhead and correspondence software enabling in situ bioprinting on curve and moving surfaces. The results of in vitro and in vivo experiments show that in situ bioprinting of bioink induces a strong hydrogel adhesion and enables printing on curved surfaces of wet tissues with a high level of fidelity. The in situ bioprinter was convenient to use in the operating room. Additional in vitro experiments (in vitro collagen contraction assay and in vitro 3D angiogenesis assay) and histological analyses demonstrated that in situ bioprinting improves the quality of wound healing in rat and porcine skin wounds.
KW - In situ bioprinting
KW - wound healing
KW - Collagen hydrogel
UR - http://www.scopus.com/inward/record.url?scp=85148208236&partnerID=8YFLogxK
U2 - 10.18063/ijb.v9i2.675
DO - 10.18063/ijb.v9i2.675
M3 - Article
SN - 2424-8002
VL - 9
SP - 380
EP - 393
JO - International Journal of Bioprinting
JF - International Journal of Bioprinting
IS - 2
M1 - 675
ER -